Triveni Bio Inc., a biotech company advancing novel antibody treatments for I&I disorders, has announced a $115 million Series B to support pipeline expansion.
The...
Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors,...
There are a lot of American startups funding deals that are creating buzz around the startup ecosystem. These are the growth-stage and early-stage deals...
858 Therapeutics, a biotechnology and drug discovery company, raised $50M in Series B funding. The round was led by Avidity Partners with participation from...
Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announced the closing of a €46.6 million (~$52...
Sequoia Biotech Consulting (Sequoia), a leading life sciences consultancy helping organizations to scale rapidly and to deliver high-quality therapeutics, and Syner-G BioPharma Group, a leading provider of integrated regulatory and biopharmaceutical development services, are excited to announce a strategic combination.
There are a lot of American startups funding deals that are creating buzz around the startup ecosystem. These are the growth-stage and early-stage deals...
Syantra, a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated, announced that it has raised an additional $4.9 million Canadian Dollars in Series A-1 funding.
Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada.
LifeSpan Vision Ventures has closed an investment in Remedium Bio. The funding will be used to advance the company’s lead candidate, RMD-1202, towards Phase 1 studies. RMD-1202 delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections - with a potentially increased safety and tolerability profile.
